Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.
Despite having been withdrawn, albiglutide is superior to placebo for reducing cardiovascular events
Read More »Albiglutide Beats Placebo for Cardiovascular Events in T2DM
High HbA1c After T1DM Diagnosis Predicts Psychiatric Comorbidity
High HbA1c levels within two years of diagnosis predict increased risk for psychiatric diagnoses
Read More »Better Glycemic Control With Closed-Loop Insulin Delivery
Better glycemic control, reduced hypoglycemia risk for T1DM patients with suboptimal glycemic control
Read More »September 2018 Briefing – Diabetes & Endocrinology
Here are what the editors at HealthDay consider to be the most important developments in Diabetes & Endocrinology for September 2018. This roundup includes the latest research news from journal articles, as well as the FDA approvals and regulatory changes that are the most likely to affect clinical practice. Increased …
Read More »Genetics May Identify Type 2 Diabetes Subtypes
Five clusters of T2DM loci and traits, each with distinct tissue-specific enhancer enrichment, identified
Read More »Risk of Venous Thromboembolism Recurrence High
At 6 months, rates for provoked, unprovoked, cancer-related VTE are 6.8, 6.92, 9.06 per 100 person-years
Read More »Increased Cardiovascular Risk for Diclofenac Initiators
Increased risk compared with NSAID non-initiators, initiators of acetaminophen, ibuprofen, naproxen
Read More »Many Countries Failing on Non-Communicable Dz Death Targets
For women and men, 35 and 30 countries expected to meet Sustainable Development Goal target 3.4
Read More »Total Diabetes at 14 Percent in U.S. Adults for 2013-2016
Prevalence of diagnosed and undiagnosed diabetes 9.7 and 4.3 percent; prevalence increased with age
Read More »Participation Up With Online Diabetes Prevention Program
But weight loss no different for online, in-person DPP for obese/overweight veterans with prediabetes
Read More »